Biosante's CEO to present an overview of the company and its impending merger with Cell Genesys

Download PDF Copy

Editorial Checklist

Reviewed

www.biosantepharma.comSep 3 2009

NewsGuard 100/100 Score

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that Stephen M. Simes, its president and CEO will present an overview of the company and its impending merger with Cell Genesys (NASDAQ: CEGE) at two healthcare investment and partnering conferences during the month of September.

The conference presentation schedule is as follows:

A live audio webcast of BioSante’s presentation at the Rodman and Renshaw conference may be accessed at http://www.wsw.com/webcast/rrshq15/bpax . A replay will be available at the same link.

Source:

www.biosantepharma.com

Posted in:

Tags: B Cell, Calcium, Cell, Contraception, Estradiol, Estrogen, H1N1, Healthcare, Menopause, Pharmaceuticals, Sexual Dysfunction, Swine Flu, T-Cell, Testosterone, Vaccine

Comments (0)

Download PDF Copy

Suggested Reading

Researchers discover mechanism affecting splicing process in retinal cells

Researchers discover mechanism affecting splicing process in retinal cells

Barcoding small extracellular vesicles with new CRISPR-based system

Barcoding small extracellular vesicles with new CRISPR-based system

Study sheds light on how cells repair damaged DNA

Study sheds light on how cells repair damaged DNA

SCimilarity revolutionizes single-cell data analysis with rapid cross-tissue comparisons

SCimilarity revolutionizes single-cell data analysis with rapid cross-tissue comparisons

Researchers reveal cellular foundations of functional brain networks in humans

Researchers reveal cellular foundations of functional brain networks in humans

Engineered SNIPRs transform CAR T-cell precision for safer cancer therapy

Engineered SNIPRs transform CAR T-cell precision for safer cancer therapy

Researchers discover how mutations disrupt protein splicing and cause disease

Researchers discover how mutations disrupt protein splicing and cause disease

Duke-NUS team develops test to monitor engineered T cells in cancer treatment

Duke-NUS team develops test to monitor engineered T cells in cancer treatment

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Liver cell aging can trigger multi-organ failure